MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

Kemas kini terakhir: semalam, 9:55AM

0.660

0.01 (1.77%)

Penutupan Terdahulu 0.648
Jumlah Dagangan 90,523
Harga / Buku (P/B) 3.34
Julat 52 Minggu
0.510 (-22%) — 1.69 (156%)
EPS Cair (TTM) -0.470
Jumlah Hutang/Ekuiti (D/E MRQ) 0.04%
Nisbah Semasa (MRQ) 12.85
Aliran Tunai Operasi (OCF TTM) -6.14 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -3.26 M
Pulangan Atas Aset (ROA TTM) -193.30%
Pulangan Atas Ekuiti (ROE TTM) -355.82%

AISkor Stockmoo

1.3
Nilai 30% 0.0
AI Insight info NA
Penilaian Relatif info NA
Kesihatan Kewangan info 0.0
Masa 30% 2.8
AI Technical info NA
Osilator Teknikal info 3.0
Purata Bergerak Teknikal info 2.5
Corak Lilin info NA
Sentimen 20% 0.0
Konsensus Penganalisis info 0.0
Sentimen Berita info NA
Wang Pintar 20% 0.8
Aktiviti Orang Dalam info NA
Aliran Institusi info 2.1
Kedudukan Jual Singkat info -2.2
Persekitaran ×1.00
Persekitaran Makro info -1.3
Sektor berbanding Pasaran (6B) +10.3%
Persetujuan Tonggak ×1.25
Tidak dikira dalam skor
Volatiliti Harga info 1.4
Skor Akhir 1.26

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok MIRA Pharmaceuticals, Inc. Bercampur Bercampur

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MIRA - - - 3.34
SNY - 5.01% - 1.40
GILD - 1.93% - 16.00
AMGN - 2.14% - 17.60
GRFS - 1.07% - 0.900
BIIB - - - 1.94

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 19.68%
% Dimiliki oleh Institusi 5.60%

Pemilikan

Nama Tarikh Syer Dipegang
Cross Staff Investments Inc 30 Sep 2026 359,401
First American Bank 30 Sep 2026 60,000

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 7.43%

Kedudukan Pemegang Saham
Bertambah 8 673,009
Berkurang 12 102,950
Baharu 2 20,841
Dijual habis 6 37,839

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 282,319 1.4
15 Oct 2026 349,714 2.4
30 Sep 2026 408,844 2.4
15 Sep 2026 447,832 1.0
31 Aug 2026 205,296 4.1
14 Aug 2026 211,083 1.5

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

Tarikh Jenis Butiran
29 Oct 2026 Yahoo Finance Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials
HANGZHOU, CHINA / ACCESS Newswire / October 29, 2026 / Inside a lab in Hangzhou, an AI system named Mira recently pushed a single-step reaction's selectivity from 51.82% to 85% in three months, without a chemist manually running the experiments.
29 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc.…
22 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable TolerabilityMIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage…
21 Oct 2026 Yahoo Finance Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Modera Wealth Management, LLC ("Modera"), a fee-only wealth management firm serving individuals, families, business owners, and nonprofit organizations, today announced it has launched Mira, a proprietary agentic AI-powered platform. Mira is designed to harmonize data and support tailored financial…
17 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral…
16 Sep 2026 Yahoo Finance Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in…
01 Sep 2026 Yahoo Finance Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech.
01 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a…

Isyarat Terkini corak lilin dan silang EMA

▲ Silang EMA menaik Sesi terakhir · 13 Nov
Jangka pendek · EMA 7/20
EMA 7 hari melintas ke atas EMA 20 hari: momentum jangka pendek berubah menaik.

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda